The release of IL-4 and TGF-β by M2 macrophages inhibit the growth of NK cells and T cells, thus resulting in reduced anti-tumor immunity in the host and insensitivity to chemotherapeutic treatments [37, 38]. The gene discussed is TGFB1; the disease is neoplasm.